Upgrades:
Intel (NASDAQ:INTC) was upgraded by analysts at Northland Securities from an “underperform” rating to a “market perform” rating in a research note issued on Monday, PriceTargets.com reports. The firm presently has a $49.00 price target on the chip maker’s stock. Northland Securities’ price target indicates a potential downside of 0.39% from the company’s current price.
A number of other equities research analysts also recently
commented on INTC. The Goldman Sachs Group restated a “sell” rating and issued
a $44.00 target price (down previously from $51.00) on shares of Intel in a
research report on Friday, October 22nd. Zacks Investment Research upgraded
Intel from a “hold” rating to a “buy” rating and set a $58.00 target price on
the stock in a research report on Friday, July 9th. Citigroup reduced their
target price on Intel from $57.00 to $52.00 and set a “neutral” rating on the
stock in a research report on Friday, October 22nd. Credit Suisse Group set a
$80.00 price objective on Intel in a report on Friday, October 22nd. Finally,
Bank of America cut their price objective on Intel from $52.00 to $45.00 and
set an “underperform” rating on the stock in a report on Friday, October 22nd.
Eleven equities research analysts have rated the stock with a sell rating,
sixteen have given a hold rating and eight have issued a buy rating to the
company’s stock. Based on data from MarketBeat.com, the company currently has a
consensus rating of “Hold” and a consensus target price of $56.52. Read
more …
Merck & Co., Inc. (NYSE:MRK) was upgraded by equities researchers at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Analyst Price Targets reports. The brokerage presently has a $110.00 price objective on the stock. Argus’ price objective would suggest a potential upside of 25.40% from the company’s previous close.
Other equities analysts have also recently issued reports
about the company. Morgan Stanley lifted their price objective on Merck &
Co., Inc. from $88.00 to $90.00 and gave the stock an “equal weight” rating in
a report on Friday. Barclays lifted their price objective on Merck & Co.,
Inc. from $87.00 to $92.00 and gave the stock an “overweight” rating in a
report on Friday, October 8th. Truist began coverage on Merck & Co., Inc.
in a research report on Tuesday, July 27th. They set a “buy” rating and a
$92.00 price target for the company. Berenberg Bank reissued a “hold” rating
and set a $92.00 price target (up previously from $86.00) on shares of Merck
& Co., Inc. in a research report on Sunday, October 10th. Finally, Zacks
Investment Research raised Merck & Co., Inc. from a “sell” rating to a
“hold” rating and set a $82.00 price target for the company in a research
report on Tuesday, August 24th. Three analysts have rated the stock with a hold
rating and nine have assigned a buy rating to the stock. According to
MarketBeat, Merck & Co., Inc. presently has an average rating of “Buy” and
an average target price of $94.16. Read
more …
Starbucks (NASDAQ:SBUX) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, The Fly reports. The firm currently has a $130.00 price objective on the coffee company’s stock, up from their previous price objective of $118.00. Stephens’ price objective indicates a potential upside of 22.56% from the stock’s previous close.
A number of other equities research analysts have also
weighed in on the stock. Piper Sandler boosted their price objective on shares
of Starbucks from $104.00 to $108.00 and gave the stock a “neutral” rating in a
report on Wednesday, July 28th. Bank of America assumed coverage on shares of
Starbucks in a report on Monday, October 11th. They issued a “buy” rating and a
$135.00 price objective for the company. Robert W. Baird lowered their price
objective on shares of Starbucks from $144.00 to $128.00 and set an
“outperform” rating for the company in a report on Friday. UBS Group lowered
their price objective on shares of Starbucks from $125.00 to $115.00 and set a
“neutral” rating for the company in a report on Friday. Finally, Atlantic
Securities downgraded shares of Starbucks from an “overweight” rating to a
“neutral” rating and set a $105.00 target price on the stock. in a research
note on Thursday, September 30th. Nine analysts have rated the stock with a
hold rating and twenty have issued a buy rating to the company. Based on data
from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus
price target of $123.00. Read
more …
Sanofi (NASDAQ:SNY) was upgraded by stock analysts at HSBC from a “hold” rating to a “buy” rating in a report released on Monday, The Fly reports.
Several other brokerages have also issued reports on SNY.
UBS Group reiterated a “buy” rating on shares of Sanofi in a research note on
Thursday, August 12th. Morgan Stanley restated an “overweight” rating on shares
of Sanofi in a research note on Friday, August 6th. Zacks Investment Research
upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a
$51.00 price objective on the stock in a research note on Wednesday, September
29th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of
Sanofi in a research note on Thursday, October 14th. Finally, SVB Leerink
upgraded shares of Sanofi from a “market perform” rating to an “outperform”
rating in a research note on Monday, September 27th. One equities research
analyst has rated the stock with a sell rating, one has issued a hold rating
and six have given a buy rating to the stock. According to data from
MarketBeat.com, the stock currently has an average rating of “Buy” and an
average price target of $51.00. Read
more …

















































